

Amendments to the Claims:

1. (Currently Amended) A method for treating overactive bladder ~~a lower urinary tract disorder~~, which comprises orally administering to an individual in need thereof a therapeutically effective amount of an active agent wherein said agent is Ziconotide (ω -conotoxin MVIIA) ~~a Cav2.2 subunit calcium channel modulator~~ or a pharmaceutically acceptable salt, ester, amide, prodrug, active metabolite or derivative thereof.
2. (Cancelled)
3. (Original) The method of claim 1, wherein the active agent is contained within a pharmaceutical formulation.
4. (Original) The method of claim 3, wherein the pharmaceutical formulation is a unit dosage formulation.
5. (Original) The method of claim 1, wherein the active agent is administered on an as-needed basis.
6. (Currently Amended) The method of claim 1, wherein the active agent is administered prior to commencement of an activity wherein suppression of the symptoms of a ~~lower urinary tract disorder~~ overactive bladder would be desirable.
7. (Original) The method of claim 6, wherein the active agent is administered from about 0 to about 3 hours prior to commencement of an activity wherein suppression of said symptoms would be desirable.
8. (Original) The method of claim 3, wherein the formulation is a controlled release dosage formulation.

9. (Original) The method of claim 8, wherein the formulation is a delayed release dosage formulation.

10. (Original) The method of claim 8, wherein the formulation is a sustained release dosage formulation.

11. (Cancelled)

12. (Original) The method of claim 10, wherein the sustained release dosage formulation provides drug release over a time period of from about 6 hours to about 8 hours.

13-28. (Cancelled)

29. (Currently Amended) The method of claim 1, wherein ~~the lower urinary tract disorder is a painful lower urinary tract disorder~~ said overactive bladder is OAB Wet.

30. (Currently Amended) The method of claim 1, wherein ~~the lower urinary tract disorder is a non-painful lower urinary tract disorder~~ said overactive bladder is OAB Dry.

31-35. (Cancelled)

36. (Original) The method of claim 3, wherein the pharmaceutical formulation further comprises an additional active agent.

37-40. (Cancelled)

Appl. No.: 10/796,952
Amdt. Dated February 27, 2006
Reply to Office action of August 30, 2005

41. (New) The method of claim 36, wherein the additional active agent is ω -conotoxin GVIA or a salt, enantiomer, analog, ester, amide, prodrug, active metabolite, or derivative thereof.